<DOC>
	<DOCNO>NCT00191321</DOCNO>
	<brief_summary>A pilot study use Teriparatide severe osteoporotic woman hip fracture submit hip replacement The primary objective study obtain preliminary data , pilot group postmenopausal woman establish osteoporosis recent hip fracture , underwent hip replacement 3-6 month screen phase , effect teriparatide : - bone turnover marker : CTx , PINP BSAP give dose 20 mcg/day subcutaneous route 18 month . The secondary objective study follow : - Effects teriparatide lumbar spine non-prosthetic femur bone density , assess BMD measurement dual energy x-ray absorptiometry ( DXA ) - Effects teriparatide quality life back pain treatment .</brief_summary>
	<brief_title>Teriparatide Use Hip Replaced Subjects</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>1 . Ambulatory postmenopausal woman establish osteoporosis , base disease diagnostic criterion 2 . Presence 1 clinical and/or radiological vertebral fracture OR 1 nonvertebral fracture 3 . Presence hip fracture hip replacement surgical procedure ( uncemented cement total hip arthroplastics endoprosthesis ) 36 month screen phase 4 . Age range 5585 year 5 . Normal clinically insignificant abnormal laboratory value ( determine investigator ) include serum calcium , PTH ( 1 84 ) , 25 hydroxyvitamin D concentration , alkaline phosphatase activity . 1 . History disease affect bone metabolism , primary postmenopausal osteoporosis , Paget 's disease , renal osteodystrophy , osteomalacia , secondary cause osteoporosis ( include glucocorticoidinduced osteoporosis ) , hypoparathyroidism , hyperparathyroidism , hyperthyroidism 2 . Actual cancer disease history malignant neoplasms 5 year prior Visit 2 , exception superficial basal cell squamous cell carcinoma skin definitively treat . Subjects carcinoma situ uterine cervix treat definitively 1 year prior entry study may enrol . 3 . Increased baseline risk osteosarcoma : Paget 's disease bone unexplained elevation alkaline phosphatase ; Prior radiation therapy involve skeleton 4 . Significantly impaired renal function 5 . Significantly impaired hepatic function</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>